Hidden complexities in assessment of glycemic outcomes: Are quality rankings aligned with treatment?

Diabetes Care

Volumn 33, Issue 10, 2010, Pages 2133-2139

  Pogach, Leonard M ^a,b   Rajan, Mangala ^a   Maney, Miriam ^a   Tseng, Chin Lin ^a,b   Aron, David C ^c,d  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ACCOUNTING; ADULT; ARTICLE; COMPLEX GLYCEMIC REGIMEN; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIABETES MELLITUS; FEMALE; GLYCEMIC CONTROL; HEALTH CARE MANAGEMENT; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; NATIONAL COMMITTEE FOR QUALITY ASSURANCE; OUTCOME ASSESSMENT; QUALITY CONTROL; SCORING SYSTEM; VETERAN;

DELIVERY OF HEALTH CARE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RETROSPECTIVE STUDIES; VETERANS HEALTH;

EID: 77956848373     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc09-1665     Document Type: Article

References (25)

1. National Committee for Quality Assurance. HEDIS 2009 Technical Specifications. Vol. 2. Washington, DC, National Committee for Quality Assurance, 2009
2. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853
3. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC, 4-T Study Group. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-1730 (Pubitemid 350005153)
4. Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Kaiser T, Plank J, Pieber TR, Siebenhofer A. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;18:CD005613
5. Bainbridge KE, Cowie CC, Rust KF, Fradkin JE. Mitigating case mix factors by choice of glycemic control performance measure threshold. Diabetes Care 2008;31:1754-1760
6. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Dudl RJ, Ismail-Beigi F, Kimel AR, Hoogwerf B, Horowitz KR, Savage PJ, Seaquist ER, Simmons DL, Sivitz WI, Speril-Hillen JM, Sweeney ME. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 8 January 2010 [Epub ahead of print]
7. Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK, Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med 2007;147:417-422
8. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, Landgraf R, Kleinebreil L. Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673-2679 (Pubitemid 43951158)
9. Kupersmith J, Francis J, Kerr E, Krein S, Pogach L, Kolodner RM, Perlin JB. Advancing evidence-based care for diabetes: lessons from the Veterans Health Administration. Health Affairs 2007;26:w156-w168
10. Pogach LM, Rajan M, Aron DC. Aligning performance measurement with clinical epidemiology: comparison of weighted performance measurement and dichotomous threshold for glycemic control in the Veterans Health Administration. Diabetes Care 2006;29:241-246 (Pubitemid 44106499)
11. Miller DR, Safford MM, Pogach LM. Who has diabetes? Best estimates of diabetes prevalence in the Veterans Health Administration based on computerized patient data. Diabetes Care 2004;27(Suppl. 2):B10-B21 (Pubitemid 38569259)
12. Sales MM, Cunningham FE, Glassman PA, Valentino MA, Good CB. Pharmacy benefits management in the Veterans Health Administration: 1995 to 2003. Am J Manag Care 2005;11:104-112
13. Pogach LM, Tiwari A, Maney M, Rajan M, Miller DR, Aron DC. Should mitigating co-morbidities be considered in assessing healthcare plan performance In achieving optimal glycemic control. Am J Manag Care 2007;13:133-140 (Pubitemid 46435372)
14. Hofer TP, Hayward RA, Greenfield S, Wagner EH, Kaplan SH, Manning WG. The unreliability of individual physician "report cards" for assessing the costs and quality of care of a chronic disease. JAMA 1999;281:2098-2105
15. State of Texas Office of Public Insurance Counsel and the Department of State Health Services Center for Health Statistics. Guide to Texas HMO Quality: 2008. Available from http://www.opic.state.tx.us/docs/544-guidetohmoquality08. pdf. Accessed 12 March 2010
16. Maney M, Tseng CL, Safford MM, Miller DR, Pogach LM. Impact of self-reported patient characteristics upon assessment of glycemic control in the Veterans Health Administration. Diabetes Care 2007;30:245-251 (Pubitemid 46198326)
17. Tran MT, Navar MD, Davidson MB. Comparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes. Diabetes Care 2006;29:1395-1396 (Pubitemid 44125944)
18. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005;28:950-955 (Pubitemid 40434505)
19. Rhoads GG, Orsini LS, Crown W, Wang S, Getahun D, Zhang Q. Contribution of hypoglycemia to medical care expenditures and short-term disability in employees with diabetes. J Occup Environ Med 2005;47:447-452 (Pubitemid 40656778)
20. Holmes EW, Erçsahin C, Augustine GJ, Charnogursky GA, Gryzbac M, Murrell JV, McKenna KM, Nabhan F, Kahn SE. Analytic bias among certified methods for the measurement of hemoglobin A1c: a cause for concern? Am J Clin Pathol 2008;129:540-547 (Pubitemid 352029272)
21. Aron DC, Pogach LM. One size does not fit all: the need for a continuous measure for glycemic control in diabetes. Jt Comm J Qual Patient Saf 2007;33:636-643
22. Burnham KP, Anderson DR. Model Selection and Multi-Model Inference: A Practical Information-Theoretic Approach. 2nd ed. New York, Springer, 2002
23. Tseng CL, Brimacombe M, Xie M, Rajan M, Wang H, Kolassa J, Crystal S, Chen TC, Pogach L, Safford M. Seasonal patterns in monthly hemoglobin A1c values. Am J Epidemiol 2005;161:565-574 (Pubitemid 40349912)
24. Shojania KG, Ranji SR, McDonald KM, Grimshaw JM, Sundaram V, Rushakoff RJ, Owens DK. Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta-regression analysis. JAMA 2006;296:427-440 (Pubitemid 44127527)
25. Kerr EA. Assessing Quality of Care for Diabetes [article online], 2008. Available from http://www.ahrq.gov/qual/diabetescare/diabetescare.pdf. Accessed 12 March, 2010